Objective: To evaluate the expression of
Vimentin and its relationship with clinical pathological data and
prognosis in
patients with metastatic
renal cell carcinoma (mRCC).
Methods: A total of 269 mRCC
patients , from June 2007 to June 2017, treated with
tyrosine kinase inhibitors (TKI) in Zhongshan
Hospital , Fudan
University were included in the study.
Vimentin was assessed by
immunohistochemistry on continuous
paraffin embedded slides. To analyzed the relationship between
Vimentin expression and clinicopathological data and
prognosis . Measurement data were expressed as mean±standard deviation ( Mean± SD). The relationship between
Vimentin expression and clinicopathological data of mRCC
patients was determined by
Chi-square test .
Survival analysis used
Kaplan-Meier survival curve , Log-rank test to judge the relationship between
Vimentin expression and
patient ′s overall
survival , and COX
regression analysis was used for univariate and
multivariate analysis .
Results: Vimentin was expressed in
cytoplasm of
tumor cells .
Vimentin expression in mRCC
patients ′
tissues was positively correlated with
tumor Fuhrman grade ( P=0.002), and negatively correlated with prognostic overall
survival ( P=0.001). Multivariate
regression analysis showed that
Vimentin expression was an independent
risk factor for overall
survival in
patients with mRCC ( P=0.006).
Conclusions: Vimentin expression can be used as a prognostic
indicator of mRCC. It is expected that
Vimentin can provide prediction for the
prognosis of mRCC
patients treated with TKI.